Brentuximab Biosimilar – Anti-TNFRSF8 mAb – Research Grade

Description of Brentuximab Biosimilar - Anti-TNFRSF8 mAb - Research Grade

Brentuximab Biosimilar – Anti-TNFRSF8 mAb – Research Grade Brentuximab Biosimilar – Anti-TNFRSF8 mAb – Research Grade Introduction

Brentuximab Biosimilar is a monoclonal antibody (mAb) that targets TNFRSF8, also known as CD30. It is a biosimilar version of the therapeutic antibody brentuximab vedotin, which is used in the treatment of various types of cancer. In this article, we will provide a scientific description of the structure, activity, and application of Brentuximab Biosimilar.

Structure of Brentuximab Biosimilar

Brentuximab Biosimilar is a chimeric antibody, meaning it is composed of both human and non-human components. It is made up of a human IgG1 constant region and a mouse-derived variable region that specifically binds to TNFRSF8. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains.

Activity of Brentuximab Biosimilar

Brentuximab Biosimilar works by binding to TNFRSF8, a protein that is overexpressed on the surface of certain cancer cells. This binding leads to the activation of immune cells, such as natural killer cells and T cells, which then target and kill the cancer cells. In addition, the antibody also induces cell death through a process known as antibody-dependent cellular cytotoxicity (ADCC), where immune cells are recruited to kill the cancer cells.

Application of Brentuximab Biosimilar

Brentuximab Biosimilar has been approved for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It is typically used in combination with chemotherapy or as a standalone treatment for patients who have relapsed or are refractory to other therapies. In addition, Brentuximab Biosimilar is also being studied for its potential in treating other types of cancer, such as non-Hodgkin lymphoma and solid tumors.

Conclusion

Brentuximab Biosimilar is a chimeric monoclonal antibody that targets TNFRSF8 and is used in the treatment of certain types of cancer. Its structure, activity, and application make it a promising therapeutic option for patients with relapsed or refractory cancer. Further research is being conducted to explore its potential in treating other types of cancer and to improve its efficacy and safety profile.

Keywords

antibody, therapeutic target, Brentuximab Biosimilar, Anti-TNFRSF8 mAb, research grade, structure, activity, application, cancer, Hodgkin lymphoma, systemic anaplastic large cell lymphoma, non-Hodgkin lymphoma, solid tumors.

SDS-PAGE for Brentuximab Biosimilar - Anti-TNFRSF8 mAb

Brentuximab Biosimilar - Anti-TNFRSF8 mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.